{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:02:03Z","timestamp":1792555323395,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T00:00:00Z","timestamp":1354147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s00406-012-0384-x","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T11:53:44Z","timestamp":1354190024000},"page":"345-352","source":"Crossref","is-referenced-by-count":125,"title":["Increased 3-Hydroxykynurenine serum concentrations differentiate Alzheimer\u2019s disease patients from controls"],"prefix":"10.1007","volume":"263","author":[{"given":"Markus J.","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles J.","family":"Guillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan J.","family":"Teipel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Buerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,29]]},"reference":[{"key":"384_CR1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1212\/WNL.42.4.733","volume":"42","author":"RL Albin","year":"1992","unstructured":"Albin RL, Greenamyre JT (1992) Alternative excitotoxic hypotheses. Neurology 42:733\u2013738","journal-title":"Neurology"},{"key":"384_CR2","unstructured":"American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. Text Revision. American Psychiatric Association, Washington, DC"},{"key":"384_CR3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s007020050149","volume":"106","author":"H Baran","year":"1999","unstructured":"Baran H, Jellinger K, Deecke L (1999) Kynurenine metabolism in Alzheimer\u2019s disease. J Neural Transm 106:165\u2013181","journal-title":"J Neural Transm"},{"key":"384_CR4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1192\/bjp.178.5.399","volume":"178","author":"C Bell","year":"2001","unstructured":"Bell C, Abrams J, Nutt D (2001) Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 178:399\u2013405","journal-title":"Br J Psychiatry"},{"key":"384_CR5","doi-asserted-by":"crossref","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6(3):131\u2013144","DOI":"10.1038\/nrneurol.2010.4"},{"key":"384_CR6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1179\/174329210X12650506623645","volume":"15","author":"DJ Bonda","year":"2010","unstructured":"Bonda DJ, Mailankot M, Stone JG, Garrett MR, Staniszewska M, Castellani RJ, Siedlak SL, Zhu X, Lee HG, Perry G, Nagaraj RH, Smith MA (2010) Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer\u2019s disease. Redox Rep 15:161\u2013168","journal-title":"Redox Rep"},{"key":"384_CR7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12640-009-9051-z","volume":"16","author":"N Braidy","year":"2009","unstructured":"Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ (2009) Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res 16:77\u201386","journal-title":"Neurotox Res"},{"key":"384_CR8","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archneur.59.8.1267","volume":"59","author":"K Buerger","year":"2002","unstructured":"Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McCulloch C, Kohnken R, Padberg F, Pirttila T, Schapiro MB, Rapoport SI, Moller HJ, Davies P, Hampel H (2002) Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 59:1267\u20131272","journal-title":"Arch Neurol"},{"key":"384_CR9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0165-5728(01)00418-0","volume":"120","author":"A Chiarugi","year":"2001","unstructured":"Chiarugi A, Calvani M, Meli E, Traggiai E, Moroni F (2001) Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J Neuroimmunol 120:190\u2013198","journal-title":"J Neuroimmunol"},{"key":"384_CR10","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1046\/j.1471-4159.2001.00335.x","volume":"77","author":"A Chiarugi","year":"2001","unstructured":"Chiarugi A, Meli E, Moroni F (2001) Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid. J Neurochem 77:1310\u20131318","journal-title":"J Neurochem"},{"key":"384_CR11","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/neu.480230915","volume":"23","author":"DW Choi","year":"1992","unstructured":"Choi DW (1992) Excitotoxic cell death. J Neurobiol 23:1261\u20131276","journal-title":"J Neurobiol"},{"key":"384_CR12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00004647-199907000-00007","volume":"19","author":"A Cozzi","year":"1999","unstructured":"Cozzi A, Carpenedo R, Moroni F (1999) Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61\u20138048) in models of focal or global brain ischemia. J Cereb Blood Flow Metab 19:771\u2013777","journal-title":"J Cereb Blood Flow Metab"},{"key":"384_CR13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1056\/NEJMra040223","volume":"351","author":"JL Cummings","year":"2004","unstructured":"Cummings JL (2004) Alzheimer\u2019s disease. N Engl J Med 351:56\u201367","journal-title":"N Engl J Med"},{"key":"384_CR14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ana.20405","volume":"57","author":"G Dal Forno","year":"2005","unstructured":"Dal Forno G, Palermo MT, Donohue JE, Karagiozis H, Zonderman AB, Kawas CH (2005) Depressive symptoms, sex, and risk for Alzheimer\u2019s disease. Ann Neurol 57:381\u2013387","journal-title":"Ann Neurol"},{"key":"384_CR15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0197-0186(95)00091-7","volume":"28","author":"LP Carvalho de","year":"1996","unstructured":"de Carvalho LP, Bochet P, Rossier J (1996) The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem Int 28:445\u2013452","journal-title":"Neurochem Int"},{"key":"384_CR16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0006-8993(89)90216-3","volume":"495","author":"CL Eastman","year":"1989","unstructured":"Eastman CL, Guilarte TR (1989) Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line. Brain Res 495:225\u2013231","journal-title":"Brain Res"},{"key":"384_CR17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1163\/156856003322315622","volume":"11","author":"SR Edwards","year":"2003","unstructured":"Edwards SR, Mather LE (2003) Diclofenac increases the accumulation of kynurenate following tryptophan pretreatment in the rat: a possible factor contributing to its antihyperalgesic effect. Inflammopharmacology 11:277\u2013292","journal-title":"Inflammopharmacology"},{"key":"384_CR18","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/j.1471-4159.1991.tb03460.x","volume":"56","author":"S Fukui","year":"1991","unstructured":"Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56:2007\u20132017","journal-title":"J Neurochem"},{"key":"384_CR19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ng1542","volume":"37","author":"F Giorgini","year":"2005","unstructured":"Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ (2005) A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 37:526\u2013531","journal-title":"Nat Genet"},{"key":"384_CR20","doi-asserted-by":"crossref","first-page":"7266","DOI":"10.1021\/bi992997s","volume":"39","author":"LE Goldstein","year":"2000","unstructured":"Goldstein LE, Leopold MC, Huang X, Atwood CS, Saunders AJ, Hartshorn M, Lim JT, Faget KY, Muffat JA, Scarpa RC, Chylack LT Jr, Bowden EF, Tanzi RE, Bush AI (2000) 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry 39:7266\u20137275","journal-title":"Biochemistry"},{"key":"384_CR21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.nbd.2004.07.006","volume":"17","author":"P Guidetti","year":"2004","unstructured":"Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington\u2019s disease. Neurobiol Dis 17:455\u2013461","journal-title":"Neurobiol Dis"},{"key":"384_CR22","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1046\/j.1460-9568.1999.00806.x","volume":"11","author":"P Guidetti","year":"1999","unstructured":"Guidetti P, Schwarcz R (1999) 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur J Neurosci 11:3857\u20133863","journal-title":"Eur J Neurosci"},{"key":"384_CR23","doi-asserted-by":"crossref","unstructured":"Guillemin GJ (2012) Quinolinic acid, the inescapable neurotoxin. FEBS J 279(8):1356\u20131365","DOI":"10.1111\/j.1742-4658.2012.08485.x"},{"key":"384_CR24","doi-asserted-by":"crossref","unstructured":"Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 78:1\u201313","DOI":"10.1046\/j.1471-4159.2001.00498.x"},{"key":"384_CR25","doi-asserted-by":"crossref","unstructured":"Guillemin GJ, Smith DG, Smythe GA, Armati PJ, Brew BJ (2003a) Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv Exp Med Biol 527:105\u2013112","DOI":"10.1007\/978-1-4615-0135-0_12"},{"key":"384_CR26","doi-asserted-by":"crossref","unstructured":"Guillemin GJ, Smythe GA, Veas LA, Takikawa O, Brew BJ (2003b) A beta 1\u201342 induces production of quinolinic acid by human macrophages and microglia. Neuroreport 14:2311\u20132315","DOI":"10.1097\/00001756-200312190-00005"},{"key":"384_CR27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2990.2005.00655.x","volume":"31","author":"GJ Guillemin","year":"2005","unstructured":"Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM (2005a) Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer\u2019s disease hippocampus. Neuropathol Appl Neurobiol 31(4):395\u2013404","journal-title":"Neuropathol Appl Neurobiol"},{"key":"384_CR28","doi-asserted-by":"crossref","unstructured":"Guillemin GJ, Smythe G, Takikawa O, Brew BJ (2005b) Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49(1):15\u201323","DOI":"10.1002\/glia.20090"},{"key":"384_CR29","doi-asserted-by":"crossref","unstructured":"Guillemin GJ, Wang L, Brew BJ (2005c) Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflammation 2:16","DOI":"10.1186\/1742-2094-2-16"},{"key":"384_CR30","doi-asserted-by":"crossref","unstructured":"Guillemin GJ, Brew BJ, Noonan CE, Knight TG, Smythe GA, Cullen KM (2007a) Mass spectrometric detection of quinolinic acid in microdissected Alzheimer's disease plaques. In: Takai K (ed) International Congress Series. pp 404\u2013408","DOI":"10.1016\/j.ics.2007.07.012"},{"key":"384_CR31","doi-asserted-by":"crossref","unstructured":"Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, Kapoor V, Takikawa O, Brew BJ (2007b) Characterization of the kynurenine pathway in human neurons. J Neurosci 27(47):12884\u201312892","DOI":"10.1523\/JNEUROSCI.4101-07.2007"},{"key":"384_CR32","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2478\/v10039-010-0023-6","volume":"55","author":"E Gulaj","year":"2010","unstructured":"Gulaj E, Pawlak K, Bien B, Pawlak D (2010) Kynurenine and its metabolites in Alzheimer\u2019s disease patients. Adv Med Sci 55:204\u2013211","journal-title":"Adv Med Sci"},{"key":"384_CR33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuint.2006.08.012","volume":"50","author":"Z Hartai","year":"2007","unstructured":"Hartai Z, Juhasz A, Rimanoczy A, Janaky T, Donko T, Dux L, Penke B, Toth GK, Janka Z, Kalman J (2007) Decreased serum and red blood cell kynurenic acid levels in Alzheimer\u2019s disease. Neurochem Int 50:308\u2013313","journal-title":"Neurochem Int"},{"key":"384_CR34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1042\/bj3260351","volume":"326","author":"MP Heyes","year":"1997","unstructured":"Heyes MP, Chen CY, Major EO, Saito K (1997) Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J 326:351\u2013356","journal-title":"Biochem J"},{"key":"384_CR35","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1523\/JNEUROSCI.21-19-07463.2001","volume":"21","author":"C Hilmas","year":"2001","unstructured":"Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463\u20137473","journal-title":"J Neurosci"},{"key":"384_CR36","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.neuint.2004.03.007","volume":"45","author":"MR Hynd","year":"2004","unstructured":"Hynd MR, Scott HL, Dodd PR (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer\u2019s disease. Neurochem Int 45:583\u2013595","journal-title":"Neurochem Int"},{"key":"384_CR37","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1471-4159.1989.tb01881.x","volume":"52","author":"M Kessler","year":"1989","unstructured":"Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with N-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52:1319\u20131328","journal-title":"J Neurochem"},{"key":"384_CR38","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/0006-8993(91)91140-V","volume":"548","author":"JY Koh","year":"1991","unstructured":"Koh JY, Choi DW (1991) Selective blockade of non-NMDA receptors does not block rapidly triggered glutamate-induced neuronal death. Brain Res 548:318\u2013321","journal-title":"Brain Res"},{"key":"384_CR39","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1096\/fj.04-3228fje","volume":"19","author":"E Kwidzinski","year":"2005","unstructured":"Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F, Nitsch R, Bechmann I (2005) Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J 19:1347\u20131349","journal-title":"FASEB J"},{"key":"384_CR40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0278-5846(03)00124-6","volume":"27","author":"EG McGeer","year":"2003","unstructured":"McGeer EG, McGeer PL (2003) Inflammatory processes in Alzheimer\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry 27:741\u2013749","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"384_CR41","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34:939\u2013944","journal-title":"Neurology"},{"key":"384_CR42","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jad.2006.07.013","volume":"98","author":"AM Myint","year":"2007","unstructured":"Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B (2007) Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 98:143\u2013151","journal-title":"J Affect Disord"},{"key":"384_CR43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1471-4159.1998.70010299.x","volume":"70","author":"S Okuda","year":"1998","unstructured":"Okuda S, Nishiyama N, Saito H, Katsuki H (1998) 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem 70:299\u2013307","journal-title":"J Neurochem"},{"key":"384_CR44","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1006\/neur.1996.0051","volume":"5","author":"AM Palmer","year":"1996","unstructured":"Palmer AM (1996) Neurochemical studies of Alzheimer\u2019s disease. Neurodegeneration 5:381\u2013391","journal-title":"Neurodegeneration"},{"key":"384_CR45","doi-asserted-by":"crossref","first-page":"e6344","DOI":"10.1371\/journal.pone.0006344","volume":"4","author":"A Rahman","year":"2009","unstructured":"Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ (2009) The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS ONE 4:e6344","journal-title":"PLoS ONE"},{"key":"384_CR46","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pnpbp.2004.11.003","volume":"29","author":"OJ Schiepers","year":"2005","unstructured":"Schiepers OJ, Wichers MC, Maes M (2005) Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 29:201\u2013217","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"384_CR47","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1755-5949.2009.00104.x","volume":"15","author":"P Schneider","year":"2009","unstructured":"Schneider P, Hampel H, Buerger K (2009) Biological marker candidates of Alzheimer\u2019s disease in blood, plasma, and serum. CNS Neurosci Ther 15:358\u2013374","journal-title":"CNS Neurosci Ther"},{"key":"384_CR48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0047-6374(01)00343-8","volume":"123","author":"P Schubert","year":"2001","unstructured":"Schubert P, Ogata T, Marchini C, Ferroni S (2001) Glia-related pathomechanisms in Alzheimer\u2019s disease: a therapeutic target? Mech Ageing Dev 123:47\u201357","journal-title":"Mech Ageing Dev"},{"key":"384_CR49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.coph.2003.10.006","volume":"4","author":"R Schwarcz","year":"2004","unstructured":"Schwarcz R (2004) The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 4:12\u201317","journal-title":"Curr Opin Pharmacol"},{"key":"384_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.102.034439","volume":"303","author":"R Schwarcz","year":"2002","unstructured":"Schwarcz R, Pellicciari R (2002) Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 303:1\u201310","journal-title":"J Pharmacol Exp Ther"},{"key":"384_CR51","doi-asserted-by":"crossref","unstructured":"Smythe GA, Braga O, Brew BJ, Grant RS, Guillemin GJ, Kerr SJ, Walker DW (2002) Concurrent quantification of quinolinic, picolinic, and nicotinic acids using electron-capture negative-ion gas chromatography\u2013mass spectrometry. Anal Biochem 301(1):21\u201326","DOI":"10.1006\/abio.2001.5490"},{"key":"384_CR52","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0197-4580(98)00022-0","volume":"19","author":"NMDA receptors belong to Institute of the Alzheimer\u2019s Association and the National Institute on Aging Working Group","year":"1998","unstructured":"The Ronald and Nancy Reagan Research Institute of the Alzheimer\u2019s Association and the National Institute on Aging Working Group (1998) Consensus report of the Working Group on: \u201cMolecular and Biochemical Markers of Alzheimer\u2019s Disease\u201d. The Ronald and Nancy Reagan Research Institute of the Alzheimer\u2019s Association and the National Institute on Aging Working Group. Neurobiol Aging 19:109\u2013116","journal-title":"Neurobiol Aging"},{"key":"384_CR53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1742-2094-6-36","volume":"6","author":"KK Ting","year":"2009","unstructured":"Ting KK, Brew BJ, Guillemin GJ (2009) Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer\u2019s disease. J Neuroinflamm 6:36","journal-title":"J Neuroinflamm"},{"key":"384_CR54","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/WNL.44.4.609","volume":"44","author":"KA Welsh","year":"1994","unstructured":"Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, Heyman A (1994) The consortium to establish a registry for Alzheimer\u2019s disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 44:609\u2013614","journal-title":"Neurology"},{"key":"384_CR55","first-page":"372","volume":"68","author":"WO Whetsell Jr","year":"1993","unstructured":"Whetsell WO Jr, Shapira NA (1993) Neuroexcitation, excitotoxicity and human neurological disease. Lab Invest 68:372\u2013387","journal-title":"Lab Invest"},{"key":"384_CR56","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","volume":"145","author":"D Zwilling","year":"2011","unstructured":"Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, Lee J, Truong J, Andrews-Zwilling Y, Hsieh EW, Louie JY, Wu T, Scearce-Levie K, Patrick C, Adame A, Giorgini F, Moussaoui S, Laue G, Rassoulpour A, Flik G, Huang Y, Muchowski JM, Masliah E, Schwarcz R, Muchowski PJ (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145:863\u2013874","journal-title":"Cell"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-012-0384-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-012-0384-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-012-0384-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T06:13:58Z","timestamp":1562393638000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-012-0384-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,29]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["384"],"URL":"https:\/\/doi.org\/10.1007\/s00406-012-0384-x","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,29]]}}}